Clinical Trial Update: Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of MT921 for submental fat has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• MT921

Snippet

Sponsor: Medy-Tox | Conditions: Submental Fat | Phase 3 | Status: COMPLETED